Medvestnik: HSCI changed its name and rebranded

list

The Human Stem Cell Institute has undergone rebranding, introducing its new corporate identity and logo, as well as a new website. The company changed its name to Artgen Biotech.

The Human Stem Cell Institute (HSCI) has rebranded, changing its name to Artgen Biotech. The company presented its new corporate identity, logo and informed about the launch of a new website. This was announced by the HSCI media office.

The decision to change the name was approved in the end of June. The goal of the rebranding is to make the company’s activities, strategy, and values more understandable to a wide range of investors and the public, says HSCI’s founder Artur Isaev.

“HSCI raised the bar many times and has become more than a stem cells institute. Today, Artgen Biotech is not only a portfolio of developments, but also an ecosystem of biotech companies,” he added.

Artgen Biotech is a biotechnology company whose goal is to create, develop and implement innovative drugs, products or methods of treatment, diagnosis and prevention into medical practice. The group includes companies at different development stages: from seed to early growth and maturity. Artgen Biotech’s developments are aimed at combating socially significant and orphan diseases.

The company was founded in 2003. In December 2009, HSCI conducted an IPO. In March 2023, its shares were listed in two Moscow Exchange indices.